Approval · Notice of Compliance 5655 · 2004

AVANDARYL: Notice of Compliance 5655

Issued October 21, 2004

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 5655
Date: October 21, 2004
Company: Glaxosmithkline IncMississauga, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Other
Therapeutic class: Antidiabetic agent

Products in this notice

Brand	DIN	Status today
AVANDARYL	02258781	Cancelled Post Market
AVANDARYL	02258803	Cancelled Post Market
AVANDARYL	02258811	Cancelled Post Market

Medicinal ingredients

GLIMEPIRIDE 1 MG per TAB
ROSIGLITAZONE MALEATE 4 MG per TAB
GLIMEPIRIDE 2 MG per TAB
GLIMEPIRIDE 4 MG per TAB